[go: up one dir, main page]

MA35062B1 - Dérivés d'amines hétérocycliques - Google Patents

Dérivés d'amines hétérocycliques

Info

Publication number
MA35062B1
MA35062B1 MA36362A MA36362A MA35062B1 MA 35062 B1 MA35062 B1 MA 35062B1 MA 36362 A MA36362 A MA 36362A MA 36362 A MA36362 A MA 36362A MA 35062 B1 MA35062 B1 MA 35062B1
Authority
MA
Morocco
Prior art keywords
group
disorders
atom
compounds
halogen
Prior art date
Application number
MA36362A
Other languages
English (en)
Inventor
Guido Galley
Roger Norcross
Philippe Pflieger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45855803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35062(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA35062B1 publication Critical patent/MA35062B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE FORMULE (I), DANS LAQUELLE R1 REPRÉSENTE UN ATOME D'HYDROGÈNE, UN GROUPE ALKYLE INFÉRIEUR, UN ATOME D'HALOGÈNE, UN GROUPE ALKYLE INFÉRIEUR SUBSTITUÉ PAR UN ATOME D'HALOGÈNE, UN GROUPE ALCOXY INFÉRIEUR, UN GROUPE ALCOXY INFÉRIEUR SUBSTITUÉ PAR UN ATOME D'HALOGÈNE, UN GROUPE CYANO, NITRO, CYCLOALKYLE EN C3 À C6, -CH2-CYCLOALKYLE EN C3 À C6, -O-CH2-CYCLOALKYLE EN C3 À C6, -O-(CH2)2-O-ALKYLE INFÉRIEUR, S(O)2CH3, SF5, -C(O)NH-ALKYLE INFÉRIEUR, PHÉNYLE, -O-PYRIMIDINYLE, ÉVENTUELLEMENT SUBSTITUÉ PAR UN ALCOXY INFÉRIEUR SUBSTITUÉ PAR UN HALOGÈNE, OU UN GROUPE BENZYLE, OXÉTANYLE OU FURANYLE; M AR REPRÉSENTE UN GROUPE ARYLE OU HÉTÉROARYLE, CHOISI DANS LE GROUPE CONSTITUÉ DU PHÉNYLE, DU NAPHTYLE, DU PYRIMIDINYLE, DU PYRIDINYLE, DU BENZOTHIAZOLYLE, DU QUINOLINYLE, DU QUINAZOLINYLE, DU BENZO[D][1.3]DIOXOLYLE, DU 5,6,7,8- TÉTRAHYDRO-QUINAZOLINYLE, DU PYRAZOLYLE, DU PYRAZINYLE, DU PYRIDAZINYLE OU DU 1,3,4-OXADIAZOLYLE; Y REPRÉSENTE UNE LIAISON, -CH2-, -CH2CH2-, -CH(CF3)- OU -CH(CH3)-; R2 REPRÉSENTE UN ATOME D'HYDROGÈNE OU UN ALKYLE INFÉRIEUR; A REPRÉSENTE CR OU N; ET R REPRÉSENTE UN ATOME D'HYDROGÈNE, UN GROUPE CYANO, UN ATOME D'HALOGÈNE OU UN ALKYLE INFÉRIEUR; R' REPRÉSENTE UN ATOME D'HYDROGÈNE OU D'HALOGÈNE; SOUS RÉSERVE QUE LORSQUE R' REPRÉSENTE UN ATOME D'HALOGÈNE, ALORS A REPRÉSENTE CH; B REPRÉSENTE CH OU N; N EST ÉGAL À 0, 1 OU 2; X REPRÉSENTE UNE LIAISON, -CH2- OU -O-. L'INVENTION CONCERNE ÉGALEMENT DES SELS D'ADDITION ACIDES PHARMACEUTIQUEMENT ACTIFS DESDITS COMPOSÉS. ON S'EST APERÇU QUE LES COMPOSÉS DE FORMULE I PRÉSENTENT UNE BONNE AFFINITÉ POUR LES RÉCEPTEURS TAAR (RÉCEPTEURS ASSOCIÉS AUX AMINES À L'ÉTAT DE TRACE), ET NOTAMMENT POUR TAAR1. LESDITS COMPOSÉS PEUVENT ÊTRE UTILISÉS EN VUE DU TRAITEMENT DE LA DÉPRESSION, DES TROUBLES ANXIEUX, DU TROUBLE BIPOLAIRE, DU TROUBLE DE L'HYPERACTIVITÉ AVEC DÉFICIT DE L'ATTENTION (THADA), DES TROUBLES DUS AU STRESS, DES PSYCHOSES TELLES QUE LA SCHIZOPHRÉNIE, DES MALADIES NEUROLOGIQUES COMME LA MALADIE DE PARKINSON, DES AFFECTIONS NEURODÉGÉNÉRATIVES COMME LA MALADIE D'ALZHEIMER, DE L'ÉPILEPSIE, DE LA MIGRAINE, DE L'HYPERTENSION, DE L'ABUS DE SUBSTANCES PSYCHOACTIVES ET D'AFFECTIONS MÉTABOLIQUES COMME LES TROUBLES DE L'ALIMENTATION, LE DIABÈTE, LES COMPLICATIONS DU DIABÈTE, L'OBÉSITÉ, LA DYSLIPIDÉMIE, LES TROUBLES DE LA CONSOMMATION ET DE L'ASSIMILATION D'ÉNERGIE, LES TROUBLES ET LE DYSFONCTIONNEMENT DE L'HOMÉOSTASIE DE LA TEMPÉRATURE CORPORELLE, LES TROUBLES DU SOMMEIL ET DU RYTHME CIRCADIEN, AINSI QUE LES AFFECTIONS CARDIOVASCULAIRES.
MA36362A 2011-03-24 2012-03-21 Dérivés d'amines hétérocycliques MA35062B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11159566 2011-03-24
PCT/EP2012/054939 WO2012126922A1 (fr) 2011-03-24 2012-03-21 Dérivés d'amines hétérocycliques

Publications (1)

Publication Number Publication Date
MA35062B1 true MA35062B1 (fr) 2014-04-03

Family

ID=45855803

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36362A MA35062B1 (fr) 2011-03-24 2012-03-21 Dérivés d'amines hétérocycliques

Country Status (23)

Country Link
US (1) US8802673B2 (fr)
EP (1) EP2688870B1 (fr)
JP (1) JP5716128B2 (fr)
KR (1) KR101518660B1 (fr)
CN (1) CN103443074B (fr)
AR (1) AR085478A1 (fr)
AU (1) AU2012230378B2 (fr)
BR (1) BR112013024312A2 (fr)
CA (1) CA2828283A1 (fr)
CL (1) CL2013002664A1 (fr)
CO (1) CO6801736A2 (fr)
CR (1) CR20130419A (fr)
EA (1) EA023237B1 (fr)
EC (1) ECSP13012896A (fr)
IL (1) IL228246A (fr)
MA (1) MA35062B1 (fr)
MX (1) MX351918B (fr)
PE (1) PE20140425A1 (fr)
PH (1) PH12013501905A1 (fr)
SG (1) SG193556A1 (fr)
UA (1) UA113167C2 (fr)
WO (1) WO2012126922A1 (fr)
ZA (1) ZA201306757B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2621050C2 (ru) 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
MX2015005721A (es) * 2012-11-07 2015-09-08 Hoffmann La Roche Derivados de pirazina.
US9738915B2 (en) 2012-12-07 2017-08-22 Merck Sharp & Dohme Corp. Biocatalytic transamination process
RU2677328C1 (ru) * 2013-12-11 2019-01-16 Ф. Хоффманн-Ля Рош Аг Способ получения хиральных 2-арилморфолинов
TN2016000447A1 (en) 2014-04-25 2018-04-04 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands.
EP3137469B1 (fr) 2014-04-28 2019-10-09 Pfizer Inc Composés hétérocycliques et leur utilisation comme ligands des récepteurs d1 de la dopamine
WO2015165085A1 (fr) * 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Dérivés de morpholine-pyridine
CN106459073B (zh) * 2014-05-28 2018-11-13 豪夫迈·罗氏有限公司 作为taar1调节剂的5-氧杂-2-氮杂二环[2.2.2]辛-4-基和5-氧杂-2-氮杂二环[2.2.1]庚-4-基衍生物
US10858326B2 (en) * 2016-05-04 2020-12-08 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
ES2926255T3 (es) 2017-04-24 2022-10-24 Tesaro Inc Métodos de fabricación de niraparib
AU2019255310B2 (en) 2018-04-18 2022-11-24 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3797108B1 (fr) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation.
GB201809102D0 (en) * 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
WO2020064792A1 (fr) 2018-09-27 2020-04-02 F. Hoffmann-La Roche Ag Composés hétérocyclyles pour le traitement d'une maladie auto-immune
WO2020062251A1 (fr) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Composés en tant qu'antagonistes du récepteur 3 de l'histamine neuronale et leurs utilisations
EP4003532B1 (fr) 2019-07-24 2024-09-04 Constellation Pharmaceuticals, Inc. Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
WO2022053541A1 (fr) * 2020-09-10 2022-03-17 Eracal Therapeutics Ltd. Composés à utiliser comme anorexigène
AR129909A1 (es) 2022-07-15 2024-10-09 Hoffmann La Roche Cetorreductasa mutante con mayor actividad de cetorreductasa así como métodos y usos de esta

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
EP2121641B1 (fr) 2007-02-15 2014-09-24 F. Hoffmann-La Roche AG 2-aminooxazolines comme ligands de taar1
BRPI0815038A2 (pt) * 2007-08-02 2015-03-17 Hoffmann La Roche Uso de derivados de benzamida para o tratamento de transtornos do cns
UY32858A (es) * 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination

Also Published As

Publication number Publication date
JP5716128B2 (ja) 2015-05-13
CR20130419A (es) 2013-10-09
EP2688870B1 (fr) 2017-02-01
CL2013002664A1 (es) 2014-05-09
AU2012230378A1 (en) 2013-09-12
HK1190703A1 (zh) 2014-07-11
CO6801736A2 (es) 2013-11-29
MX351918B (es) 2017-11-03
CA2828283A1 (fr) 2012-09-27
JP2014508790A (ja) 2014-04-10
BR112013024312A2 (pt) 2016-07-19
SG193556A1 (en) 2013-11-29
NZ616150A (en) 2014-09-26
KR20130132656A (ko) 2013-12-04
IL228246A (en) 2017-10-31
EA023237B1 (ru) 2016-05-31
UA113167C2 (xx) 2016-12-26
US8802673B2 (en) 2014-08-12
AR085478A1 (es) 2013-10-02
EP2688870A1 (fr) 2014-01-29
US20120245172A1 (en) 2012-09-27
KR101518660B1 (ko) 2015-05-07
EA201391341A1 (ru) 2014-06-30
ECSP13012896A (es) 2013-11-29
ZA201306757B (en) 2015-04-29
AU2012230378B2 (en) 2016-09-15
CN103443074B (zh) 2016-04-13
PH12013501905A1 (en) 2019-10-11
WO2012126922A1 (fr) 2012-09-27
MX2013010954A (es) 2013-10-07
PE20140425A1 (es) 2014-03-28
CN103443074A (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
MA35062B1 (fr) Dérivés d'amines hétérocycliques
MA35192B1 (fr) Derives de pyrazole
MA35194B1 (fr) Derives de benzamide substitues
CN1291717C (zh) 止痒药物
MA32486B1 (fr) Derives de 4,5- dihydrooxazol-2-yle
MA42442B1 (fr) Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
DE60309057T2 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
Hagen et al. 2-Iminopyrrolidines as potent and selective inhibitors of human inducible nitric oxide synthase
MA31165B1 (fr) Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc
MA31865B1 (fr) Dérivés isoxazolo-pyridine
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
JP2010531837A (ja) 微量アミン関連レセプター（ｔａａｒ）に対して良好な親和性を有する２−イミダゾリン
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
MA35133B1 (fr) Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5
TW200738690A (en) Use of 2-imidazoles for the treatment of CNS disorders
FR2681325A1 (fr) Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
MA37944A1 (fr) Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson
MA38885A1 (fr) Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4)
MX2009005920A (es) Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
MX2009006215A (es) 4-imidazolinas como ligandos de aminas trazas.
MX2009013745A (es) 4-imidazolinas y su uso como antidepresivos.
MA38011B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5
MX2009004617A (es) 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina.
CA2663080A1 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique.
MX349738B (es) Derivados de dihidrooxazol-2-amina.